Determinants of progression in idiopathic pulmonary fibrosis
- PMID: 8306043
- DOI: 10.1164/ajrccm.149.2.8306043
Determinants of progression in idiopathic pulmonary fibrosis
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive form of lung disease with a median survival of less than 5 yr. To address the progressive nature of this disease process, we investigated the determinants of decrements in lung function in patients with IPF. We prospectively evaluated 39 subjects with IPF. Our study subjects were followed for an average of 2 yr (range, 49 to 1,883 days) and lung function was measured on at least two separate occasions (mean = 9.1 separate tests) during the follow-up period. Since IPF is characterized by reduced lung volume and abnormal gas exchange, our analysis focused on the determinants of total lung capacity (TLC) and diffusing capacity of carbon monoxide (DLCO) during the period of observation. Although, on average, there was a 5.3% increase in the TLC and a 9.8% increase in DLCO between the first and last measure of lung function, 25% of the study population experienced a decline in the TLC and 28% of the study population experienced a decline in the DLCO. Decrements in TLC were independently associated with severe dyspnea (p = 0.01) and treatment with cyclophosphamide (p = 0.03). Decrements in DLCO were significantly and independently associated with more pack-years of cigarette smoking (p = 0.02), moderate (p = 0.03) or severe (p = 0.02) dyspnea, and treatment with cyclophosphamide (p = 0.0002). These findings indicate that several clinical characteristics are independently associated with subsequent declines in TLC and DLCO in patients with IPF.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Determinants of survival in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med. 1994 Feb;149(2 Pt 1):450-4. doi: 10.1164/ajrccm.149.2.8306044. Am J Respir Crit Care Med. 1994. PMID: 8306044
-
Longitudinal changes in lung function among asbestos-exposed workers.Am J Respir Crit Care Med. 1994 Nov;150(5 Pt 1):1243-9. doi: 10.1164/ajrccm.150.5.7952547. Am J Respir Crit Care Med. 1994. PMID: 7952547
-
Determinants of response to immunosuppressive therapy in idiopathic pulmonary fibrosis.Eur Respir J. 1994 Nov;7(11):1950-7. Eur Respir J. 1994. PMID: 7875264
-
Clinical and functional assessment of patients with idiopathic pulmonary fibrosis: results of a 3 year follow-up.Eur Respir J. 1994 Apr;7(4):643-50. doi: 10.1183/09031936.94.07040643. Eur Respir J. 1994. PMID: 8005243
-
Office-based DLCO tests help pulmonologists to make important clinical decisions.Respir Investig. 2016 Sep;54(5):305-11. doi: 10.1016/j.resinv.2016.03.006. Epub 2016 May 2. Respir Investig. 2016. PMID: 27566377 Review.
Cited by
-
Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.Drugs. 2004;64(4):405-30. doi: 10.2165/00003495-200464040-00005. Drugs. 2004. PMID: 14969575 Review.
-
Raised plasma concentrations of alpha-defensins in patients with idiopathic pulmonary fibrosis.Thorax. 2002 Jul;57(7):623-8. doi: 10.1136/thorax.57.7.623. Thorax. 2002. PMID: 12096207 Free PMC article.
-
Urokinase-type plasminogen activator receptor (uPAR) ligation induces a raft-localized integrin signaling switch that mediates the hypermotile phenotype of fibrotic fibroblasts.J Biol Chem. 2014 May 2;289(18):12791-804. doi: 10.1074/jbc.M113.498576. Epub 2014 Mar 18. J Biol Chem. 2014. PMID: 24644284 Free PMC article.
-
The biology of the ABCA3 lipid transporter in lung health and disease.Cell Tissue Res. 2017 Mar;367(3):481-493. doi: 10.1007/s00441-016-2554-z. Epub 2016 Dec 26. Cell Tissue Res. 2017. PMID: 28025703 Free PMC article. Review.
-
Comparison between conventional and "clinical" assessment of experimental lung fibrosis.J Transl Med. 2008 Apr 10;6:16. doi: 10.1186/1479-5876-6-16. J Transl Med. 2008. PMID: 18402687 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical